INTRODUCTION
In the recent years, mycobacterial proteins have gained special attention as suitable candidates for subunit antituberculous vaccine (1) . A number of native and recombinant proteins have been characterized for their ability to achieve TH1 cells involved in the induction of protective immunity against tuberculosis (1) . However, most of these proteins are weakly immunogenic if administered without an adjuvant. Hence, to improve vaccine efficacy, evaluation of new vaccine delivery systems based on pharmaceutically acceptable, controlled antigen delivery systems need to be identified.
Presently, synthetic, biodegradable polymers have gained considerable attention as adjuvants because of their potential for long term controlled release of proteins (2) . Copolymers of lactide and glycolide such as DL-PLG have been demonstrated to have strong adjuvanticity for various antigenic proteins including ovalbumin, cholera toxoid, tetanus toxoid, malaria and pnemotrophic bacterial antigens (2) .
Address for Correspondance : Dr. G.K. Khuller at above address In the present study, a highly immunoreactive 71 kDa cell wall associated protein of M. tuberculosis H37Ra was entrapped in PLG-MPs to evaluate its immunogenicity and protective efficacy against tuberculosis. The protein has been previously reported to induce better protection than BCG against LDso challenge of M. tuberculosis H37Ra in mice when complexed in FIA (3).
IMMUNE RESPONSES TO 71 kDa-PLG MICROPARTICLES
The 71 kDa protein was isolated from M. tuberculosis H37Ra cells as described previously (3) and homogeneity of the protein was checked by silver staining on 12% SDS-PAGE. 71 kDa-PLG microparticles were prepared by double emulsion solvent evaporation technique (4) . The results suggest that PLG microparticles induced higher and prolonged T cell response in comparision to FIA, which were skewed towards TH1 subset, known to impart protection against tuberculosis as demonstrated previously by Vordermeir et at (4).
PROTECTIVE EFFICACY OF 71 kDa-PLG MICROPARTICLES
The protection induced by 71 kD.a-FIA, 71 kDa-PLG-MPs and BCG immunization was assessed by monitoring the survival rates and colony forming units (CFUs) enumeration at 30 days post challange (p.c. with LDso of M. tuberculosis H37Rv (3 x 107 CFUs/mouse). BCG vaccinated group was injected 1 x 106 viable M. bovis BCG subcutaneously.
At thirty days p.c. 71 kDa induced marginally higher percent survival (85%) as compared to 71 kDa-FIA and BCG (60-70%) when challenged at sixteenth week p.im.
The number of viable bacilli recovered from infected organs of 71 kDa-PLG-MPs and 71 kDa-FIA immunized mice exhibited significant-decrease in comparison to controls as well as BCG vaccinated mice. However, the clearance of bacterial load was significantly higher in 71 kDa-PLG immunized group (p<0.001) as compared to 71 kDaFlA. (Table 1) The highly significant and sustained protective effect of 71 kDa-PLG microparticles suggests that administration of protective antigens in appropriate adjuvant can induce a long lived protective response. The long term protective effect of 71 kDa-PLG is mediated by slow and persistent release of antigen at predetermined rates for prolonged periods, which can be achieved by choice of appropriate particle size and blending of component ratios. Previously, Anderson (5) has reported specific long term protection to soluble mixture of secretory proteins using DDA (dimethyl deoctadecyl ammonium bromide) as adjuvant at challenge 2-3 weeks p. im. However, PLG microparticles have advantage over other adjuvants like DDA and FIA due to their tissue compatibility, proven adjuvanticity when adminstered orally or intranasally (6) and have already been recommended for human use (6) .
In conclusion, we for the first time report PLG-MPs as extremely potent delivery systems for immunoprotective mycobacterial antigens in induction of long term protective effect.
